Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Forsberg, Lisa ^a,b   Navér, Lars ^a,b   Gustafsson, Lars L ^b   Wide, Katarina ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; GLUCOSE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEONATAL ABSTINENCE SCORE; NEONATAL MALADAPTATION SYNDROME; NEONATAL WARD; NEWBORN; NEWBORN DISEASE; PEDIATRIC WARD; PREMATURITY; PRENATAL DRUG EXPOSURE; PREVALENCE; RETROSPECTIVE STUDY; SCORING SYSTEM; SWEDEN; THIRD TRIMESTER PREGNANCY; UNIVERSITY HOSPITAL; ADAPTATION; DIAGNOSIS; ENVIRONMENTAL EXPOSURE; INFANT; PREGNANCY; PRENATAL EXPOSURE; RISK FACTOR;

ADAPTATION, BIOLOGICAL; ADULT; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84909594522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111327     Document Type: Article

References (26)

1. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, et al. (2008) Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 65: 805-815.
2. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, et al. (2011) Drug use during pregnancy in Sweden-assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol 3: 43-50.
3. Lennestal R, Kallen B (2007) Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27: 607-613.
4. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, et al. (2013) Prevalence of antidepressant use during pregnancy in Denmark, a nationwide cohort study. PLoS One 8: e63034.
5. Reis M, Kallen B (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40: 1723-1733.
6. Berard A, Ramos E, Rey E, Blais L, St-Andre M, et al. (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80: 18-27.
7. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, et al. (2005) Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293: 2372-2383.
8. Laine K, Heikkinen T, Ekblad U, Kero P (2003) Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60: 720-726.
9. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, et al. (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344: d8012.
10. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, et al. (2004) Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49: 726-735.
11. Finnegan LP, Connaughton JF, Jr., Kron RE, Emich JP (1975) Neonatal abstinence syndrome: assessment and management. Addict Dis 2: 141-158.
12. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160: 173-176.
13. Sarman I (2000) [Methadone treatment during pregnancy and its effect on the child. Better than continuing drug abuse, should be monitored by a specialized antenatal care center]. Lakartidningen 97: 2182-2184, 2187-2188, 2190.
14. Socialstyrelsen (2013) Statistikdatabasen. In: Socialstyrelsen, editor. wwwsocialstyrelsense. www.socialstyrelsen.se.
15. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, et al. (2009) Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42: 95-100.
16. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, et al. (2004) Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65: 230-237.
17. Kallen B (2004) Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158: 312-316.
18. Hawdon JM, Ward Platt MP, Aynsley-Green A (1992) Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. Arch Dis Child 67: 357-365.
19. Boardman JP, Wusthoff CJ, Cowan FM (2013) Hypoglycaemia and neonatal brain injury. Arch Dis Child Educ Pract Ed 98: 2-6.
20. Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM (1999) Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. J Pediatr 134: 492-498.
21. Winklbaur B, Baewert A, Jagsch R, Rohrmeister K, Metz V, et al. (2009) Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 15: 150-156.
22. Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, et al. (2013) Short-Term Neonatal Outcome among Term Infants after in utero Exposure to Serotonin Reuptake Inhibitors. Neonatology 104: 65-70.
23. Warburton W, Hertzman C, Oberlander TF (2010) A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 121: 471-479.
24. Hilli J, Heikkinen T, Rontu R, Lehtimaki T, Kishida I, et al. (2009) MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol 19: 363-370.
25. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, et al. (2008) Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 13: 65-73.
26. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, et al. (2008) Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 63: 267-279.